chronic kidney disease
Endocrinology · 2020–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| dapagliflozin To reduce the risk of progressive decline in kidney function in adults with proteinuric chronic kidney disease (CKD Stage 2, 3 or 4). | Sep 2025 | Recommended with restriction | input received Australian Diabetes Society |
| empagliflozin Extension of listing for chronic kidney disease (CKD) to include additional patient subgroups with eGFR 20–90 mL/min/1.73 m² and varying urinary… | May 2025 | Recommended with restriction | input received Australian Diabetes Society |
| empagliflozin Treatment of chronic kidney disease to reduce the risk of kidney disease progression, cardiovascular death, and all-cause hospitalisation in adult patients… | Nov 2023 | Recommended with restriction | 3 individuals Kidney Health Australia · National Aboriginal Community Controlled Health Organisation |
| dapagliflozin Treatment of chronic kidney disease (CKD Stage 2, 3 or 4) to reduce the risk of progressive decline in kidney function in adults with proteinuric chronic… | Mar 2022 | Recommended | input received Kidney Health Australia · Diabetes Australia |
| dapagliflozin Treatment of chronic kidney disease in adults with eGFR ≥25 to ≤75 mL/min/1.73 m² and UACR ≥200 to ≤5000 mg/g who are stable on maximum tolerated dose of ACEI… | Sep 2021 | Deferred | 9 individuals Diabetes Australia · Kidney Health Australia · National Aboriginal Community Controlled Health Organisation |
| dapagliflozin Treatment of chronic kidney disease in adults with eGFR ≥25 to ≤75 mL/min/1.73 m², UACR ≥200 and ≤5000 mg/g, stable on maximum tolerated dose of ACEI or ARB. | Jul 2021 | Deferred | 9 individuals Diabetes Australia · Kidney Health Australia · National Aboriginal Community Controlled Health Organisation |
| dapagliflozin Treatment of chronic kidney disease (CKD) in patients with eGFR ≥25 to ≤75 mL/min/1.73 m², UACR ≥200 and ≤5000 mg/g, stable on maximum tolerated dose of ACEI… | Nov 2021 | Deferred | 9 individuals Diabetes Australia · Kidney Health Australia · National Aboriginal Community Controlled Health Organisation |
| whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, low in protein, phosphate, potassium and lactose Dietary management of chronic kidney disease (CKD) in infants and young children. | Mar 2020 | Recommended with restriction | none received |
Who spoke
Kidney Health Australia · Diabetes Australia · National Aboriginal Community Controlled Health Organisation · Australian Diabetes Society
What the PBS pays
$323M in government benefit over 2024–25, across 5,915,466 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| empagliflozin | $186.5M |
| dapagliflozin | $114.2M |
| whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, low in protein, phosphate, potassium and lactose | $21.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.